A number of other equities analysts have also weighed in on BTG. Peel Hunt reiterated a hold rating and issued a GBX 670 ($8.75) price target (up previously from GBX 640 ($8.36)) on shares of BTG in a research report on Tuesday, November 13th. JPMorgan Chase & Co. increased their price target on BTG from GBX 650 ($8.49) to GBX 680 ($8.89) and gave the company a neutral rating in a research report on Wednesday, November 14th. Deutsche Bank reiterated a hold rating and issued a GBX 645 ($8.43) price target on shares of BTG in a research report on Tuesday, September 4th. Numis Securities reiterated a buy rating on shares of BTG in a research report on Thursday, October 4th. Finally, Shore Capital reiterated a buy rating on shares of BTG in a research report on Thursday, October 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of GBX 732.50 ($9.57).
LON:BTG opened at GBX 828.25 ($10.82) on Tuesday. BTG has a 1-year low of GBX 559.82 ($7.32) and a 1-year high of GBX 784 ($10.24).
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
See Also: Bond
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.